Page last updated: 2024-12-09

2-mercaptonicotinic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-mercaptonicotinic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID673681
CHEMBL ID1521174
SCHEMBL ID261186
MeSH IDM0222090

Synonyms (61)

Synonym
AC-6146
BB 0242382
2-mercaptopyridine-3-carboxylic acid, technical grade
AI-204/31702063
2-sulfanylnicotinic acid
MLS000779168
smr000415864
2-mercapto-nicotinic acid
MAYBRIDGE4_003766
2-sulfanylpyridine-3-carboxylic acid
STK502131
2-mercaptonicotinic acid
HMS1531L04
AKOS000118869
AKOS001058272
38521-46-9
M1213
2-mercapto-3-pyridinecarboxylic acid
2-sulfanylidene-1h-pyridine-3-carboxylic acid
2-mercapto-nicotinic acid;2-mercaptonicotinic acid
A6522
NCGC00246502-01
2-mercaptopyridine-3-carboxylic acid
2-mercaptonicotinicacid
BBL005413
eu7d859abz ,
3-pyridinecarboxylic acid, 1,2-dihydro-2-thioxo-
unii-eu7d859abz
2-thionicotinic acid
HMS2762C10
F1716-0347
FT-0612767
FS-2590
AM20061759
CHEMBL1521174
1,2-dihydro-2-thioxopyridine-3-carboxylic acid
SCHEMBL261186
WYKHFQKONWMWQM-UHFFFAOYSA-N
3-aza-2-thiosalicylic acid
1,2-dihydro-2-thioxo-3-pyridinecarboxylic acid
2-mercapto-3-carboxypyridine
2-thioxo-1h-pyridine-3-carboxylic acid
J-503823
DTXSID9068110
STR00420
mfcd00010102
2-sulfanylidene-1,2-dihydropyridine-3-carboxylic acid
mfcd01104135
bdbm50486219
mnt-h
CS-W020029
SY018289
F14851
2-mercaptopyridine-3-carboxylic acid;2-mercapto-nicotinic acid
BCP30026
EN300-17611
STL191152
2-thioxo-1,2-dihydropyridine-3-carboxylic acid
Q27277372
2-mercapto nicotinic acid
Z203045100

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"This study was aimed to synthesize polymeric excipients with improved mucoadhesive, cohesive and in situ-gelling properties to assure a prolonged retention time of dosage forms at a given target site, thereby achieving an increased uptake and improved oral bioavailability of certain challenging therapeutic agents such as peptides and proteins."( Preactivated thiomers as mucoadhesive polymers for drug delivery.
Bernkop-Schnürch, A; Dünnhaupt, S; Hintzen, F; Iqbal, J; Müller, C; Shahnaz, G, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
"This study was aimed to synthesize polymeric excipients with improved mucoadhesive, cohesive and in situ-gelling properties to assure a prolonged retention time of dosage forms at a given target site, thereby achieving an increased uptake and improved oral bioavailability of certain challenging therapeutic agents such as peptides and proteins."( Preactivated thiomers as mucoadhesive polymers for drug delivery.
Bernkop-Schnürch, A; Dünnhaupt, S; Hintzen, F; Iqbal, J; Müller, C; Shahnaz, G, 2012
)
0.38
" Multiunit dosage form properties of the resulting conjugate (Pec-Cys-MNA) were compared to unmodified pectin and the intermediate thiolated using rosuvastatin calcium as a model drug in loaded minitablets."( Preactivated thiomers: evaluation of gastroretentive minitablets.
Bernkop-Schnürch, A; Dünnhaupt, S; Hauptstein, S; Laffleur, F; Müller, C, 2013
)
0.39
" Accordingly, preactivated thiolated NPs providing a prolonged residence time on mucosal membranes could be a promising dosage form for various applications."( Preactivated thiolated nanoparticles: A novel mucoadhesive dosage form.
Bernkop-Schnürch, A; Bonengel, S; Laffleur, F; Menzel, C; Pereira de Sousa, I; Prüfert, F, 2016
)
0.43
"The aim of the present study was to establish a novel polymeric excipient for liquid nasal dosage forms exhibiting viscosity increasing properties, improved mucoadhesion and stability towards oxidation in solution."( Nasal drug delivery: Design of a novel mucoadhesive and in situ gelling polymer.
Bernkop-Schnürch, A; Jelkmann, M; Laffleur, F; Menzel, C, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency4.45630.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency0.89130.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency17.78280.177814.390939.8107AID2147
glp-1 receptor, partialHomo sapiens (human)Potency28.18380.01846.806014.1254AID624417
phosphopantetheinyl transferaseBacillus subtilisPotency8.91250.141337.9142100.0000AID1490
GLS proteinHomo sapiens (human)Potency28.18380.35487.935539.8107AID624170
Microtubule-associated protein tauHomo sapiens (human)Potency37.64600.180013.557439.8107AID1460; AID1468
thioredoxin glutathione reductaseSchistosoma mansoniPotency100.00000.100022.9075100.0000AID485364
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency39.81070.707912.194339.8107AID720542
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency39.81070.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.54810.035520.977089.1251AID504332
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency6.30960.036619.637650.1187AID2100
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency33.58750.168316.404067.0158AID720504
eyes absent homolog 2 isoform aHomo sapiens (human)Potency100.00001.199814.641950.1187AID488837
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency31.62280.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)80.00000.03403.987110.0000AID1082239
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID1082237Inhibition of xanthine oxidase2011Journal of agricultural and food chemistry, May-11, Volume: 59, Issue:9
Neonicotinoid insecticides: oxidative stress in planta and metallo-oxidase inhibition.
AID1082232Inhibition of xanthine oxidase at IC50 concentration2011Journal of agricultural and food chemistry, May-11, Volume: 59, Issue:9
Neonicotinoid insecticides: oxidative stress in planta and metallo-oxidase inhibition.
AID1082239Inhibition of Agaricus bisporus (mushroom) tyrosinase2011Journal of agricultural and food chemistry, May-11, Volume: 59, Issue:9
Neonicotinoid insecticides: oxidative stress in planta and metallo-oxidase inhibition.
AID1082231Inhibition of Oryctolagus cuniculus (rabbit) AOX in liver cytosol at IC50 concentration2011Journal of agricultural and food chemistry, May-11, Volume: 59, Issue:9
Neonicotinoid insecticides: oxidative stress in planta and metallo-oxidase inhibition.
AID1082236Inhibition of Bos taurus (bovine) CAT in liver2011Journal of agricultural and food chemistry, May-11, Volume: 59, Issue:9
Neonicotinoid insecticides: oxidative stress in planta and metallo-oxidase inhibition.
AID1082238Inhibition of Oryctolagus cuniculus (rabbit) AOX in liver cytosol2011Journal of agricultural and food chemistry, May-11, Volume: 59, Issue:9
Neonicotinoid insecticides: oxidative stress in planta and metallo-oxidase inhibition.
AID1721328Substrate-dependent activation of HDAC8 (unknown origin) assessed as fold activation using FLUOR DE LYS as substrate at 20 uM incubated for 30 mins by fluorescence based assay relative to control2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
An in silico mechanistic insight into HDAC8 activation facilitates the discovery of new small-molecule activators.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (8.82)29.6817
2010's27 (79.41)24.3611
2020's4 (11.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.84 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index4.85 (4.65)
Search Engine Demand Index27.14 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]